Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DPX-101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Damona Pharmaceuticals Receives IND Clearance for DPX-101 Phase 1 Trial in Brain Disorders
Details : DPX-101 is an investigational positive allosteric modulator (PAM) that selectively targets the α5 subunit of the GABA-A receptor for the potential treatment of cognitive deficits in MDD.
Brand Name : DPX-101
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 04, 2024
Lead Product(s) : DPX-101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?